Background: Hirsutism is an important array of clinical syndrome that ranges from various dermatological to gynecological concerns. This is characterized by growth terminal hairs in women in male-pattern. Aim: To compare the efficacy of Nd-YAG laser with adjuvant eflornithine cream versus Nd-YAG laser treatment alone for facial hirsutism in women. Methods: It was a Randomized Controlled Trial conducted in the Department of Dermatology, Shalamar Hospital, Lahore from 25th February, 2020 to 25th October, 2020. Sampling technique used was probability consecutive sampling. In this study female cases with age 18-40 years with Fitzpatrick type III-IV were enrolled having facial hirsutism for > 6 months and were randomly allocated in two groups A and B. In group A, cases were provided with eflornithine cream to apply on face after cleaning and drying in the form of a thin film only on the treatment area every night. Results: A total 162 cases (81 in each group) were enrolled in this study. Mean age of the subjects in group B and A was 30.23±5.43 vs 30.94±4.88 years. Efficacy was observed in 64(79.01%) cases in group B managed with ND-Yag laser alone and 78(96.30%) cases in group A managed with ND-Yag laser along with Eflornithine with p=0.001. For age group 30-40 years efficacy in group B was 41(80.39%) cases and in all the 49(100%) cases in group A with p= 0.001.In cases with BMI up to 25 kg/m2 efficacy in group B and A was observed in 44(88%) vs 49(100%) cases (p=0.03) and those with BMI more than this, this efficacy was found in 20(64.52%) and 29(90.63%) cases respectively with p=0.02. Conclusion: Efficacy in facial hirsutism is significantly better in ND-Yag laser combined with Eflornithine as compared to ND-Yag laser alone and this difference is also significantly better for combination group in terms of age group 30-40 years, BMI up to 25mg/m2 and in those with duration of complaint upto 2 years. Keywords: Hirsutism, Efficacy, Eflornithine, Nd-YAG laser

Background: Warts are the hard, hyperkeratotic benign growths over the skin caused by human papilloma virus. It is one of the common skin conditions presented to the outpatient department. Various treatment options are available with variable success but sometimes it is resistant to treatment due to its depth in the dermis and relapsing nature. Aim: To compare clinical efficacy of 0.1% intralesional bleomycin solution and 0.05% intralesionalbleomycin solution in the patients with warts. Study settings & design: Experimental, Dermatology, LUMHS Jamshoro Duration: 1st January 2018 to 30th June 2018 Methods: 90 patients with persistent common warts were enrolled. Patients were examined and number of warts located on right and left hand, feet and leg of each patient were categorized in two groups as right sided group and left sided group respectively. The two concentrations of bleomycin were randomly adminitered to either right sided and left sided warts which are called, the lesion A in which 0.1% IL bleomycin solution was injected and the lesion B in which 0.05% IL bleomycin solution was injected respectively. The Response of the both therapies was assessed by measuring the size of warty lesions on 6thweek. Then patient was advised to report at the end of 14th week to observe any recurrence in the treated lesions and to assess the final clinical efficacy. Results: - Mean age of patients was 25.36 ± 6.09 years. There were 50(55.56%) male and 40(44.44%) females. Clinical efficacy as per operational definition i.e. Complete disappeared or >50% regression in size of warts with no recurrence was significantly high in lesion A than lesion B [93.3% vs. 68.9%; p=0.0005]. Regarding number of warts in patients, 86.1% of the warts were cured in lesion A while 64.9% were cure in lesion B. The difference was statistically significant. Conclusion: - Our results support that 0.1% IL Bleomycin is more effective in the treatment of viral warts as compared to 0.05% bleomycin. Keywords: Common Warts, Intralesional, Bleomycin treatment